Document is current
Any future updates will be listed below
-
Authors
Andrews, Miles C. https://orcid.org/0000-0003-1231-8641
Oba, Junna https://orcid.org/0000-0002-2899-3919
Wu, Chang-Jiun https://orcid.org/0000-0001-8350-6397
Zhu, Haifeng
Karpinets, Tatiana
Creasy, Caitlin A.
Forget, Marie-Andrée
Yu, Xiaoxing
Song, Xingzhi
Mao, Xizeng
Robertson, A. Gordon
Romano, Gabriele
Li, Peng
Burton, Elizabeth M.
Lu, Yiling
Sloane, Robert Szczepaniak
Wani, Khalida M.
Rai, Kunal https://orcid.org/0000-0003-2321-6894
Lazar, Alexander J. https://orcid.org/0000-0002-6395-4499
Haydu, Lauren E. https://orcid.org/0000-0002-6360-0199
Bustos, Matias A. https://orcid.org/0000-0001-9625-1127
Shen, Jianjun
Chen, Yueping
Morgan, Margaret B.
Wargo, Jennifer A. https://orcid.org/0000-0003-3438-7576
Kwong, Lawrence N.
Haymaker, Cara L. https://orcid.org/0000-0002-1317-9287
Grimm, Elizabeth A.
Hwu, Patrick
Hoon, Dave S. B. https://orcid.org/0000-0003-1915-3683
Zhang, Jianhua https://orcid.org/0000-0001-5412-9860
Gershenwald, Jeffrey E. https://orcid.org/0000-0003-4519-5369
Davies, Michael A. https://orcid.org/0000-0002-0977-0912
Futreal, P. Andrew https://orcid.org/0000-0001-8663-2671
Bernatchez, Chantale https://orcid.org/0000-0001-5926-3460
Woodman, Scott E. https://orcid.org/0000-0002-1157-6991
-
Funding
Funding for this research was provided by:
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
AIM at Melanoma
- License Information
-
More Information
Article History
Received: 9 March 2021
Accepted: 20 June 2022
First Online: 9 July 2022
Competing interests
: M.C.A. reports advisory board participation, honoraria and research funding to institution from Merck Sharp and Dohme, and contract research for BMS Australia, all outside the submitted work. M.C.A. and J.A.W. are co-inventors on patent applications “Methods and compositions for treating cancer” (WO2020106983A1) and “Methods for improving sex-dimorphic responses to targeted therapy in melanoma” (US20200164034A1), unrelated to the current work. M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, and ABM Therapeutics, and has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad and Oncothyreon. J.A.W. is an inventor on patent applications submitted by the University of Texas MD Anderson Cancer Center “Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome” (PCT/US17/53.717) and “Targeting B cells to enhance response to immune checkpoint blockade” (UTSC.P1412US.P1-MDA19-023); reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb; serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, and Ella Therapeutics. AJL reports personal fees from Merck, Bristol-Myers Squibb, Novartis, and Roche/Genentech; personal fees and non-financial support from ArcherDX and Beta-Cat; grants and non-financial support from Medimmune/AstraZeneca and Sanofi; and grants, personal fees and non-financial support from Janssen, all outside the submitted work. J.E.G. reports consulting and/or advisory roles to Merck, Novartis, Syndax, Bristol-Myers Squibb, Regeneron, unrelated to this work. P.H. reports consulting/advisory roles for Dragonfly, Immatics, GSK, and Sanofi. C.B. reports consulting for and receiving funding from Iovance Biotherapeutics and Obsidian Therapeutics as well as serving as a consultant/advisory board member for Myst Therapeutics and Turnstone Biologics. All other authors report no relevant disclosures.
